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Abstract
Fe supplementation is a common strategy to correct Fe-deficiency anaemia in children; however, it may modify the gut microbiota and
increase the risk for enteropathogenic infection. In the present study, we studied the impact of Fe supplementation on the abundance
of dominant bacterial groups in the gut, faecal SCFA concentration and gut inflammation in children living in rural South Africa. In a
randomised, placebo-controlled intervention trial of 38 weeks, 6- to 11-year-old children with Fe deficiency received orally either tablets
containing 50 mg Fe as FeSO4 (n 22) for 4 d/week or identical placebo (n 27). In addition, Fe-sufficient children (n 24) were included as
a non-treated reference group. Faecal samples were analysed at baseline and at 2, 12 and 38 weeks to determine the effects of Fe
supplementation on ten bacterial groups in the gut (quantitative PCR), faecal SCFA concentration (HPLC) and gut inflammation (faecal
calprotectin concentration). At baseline, concentrations of bacterial groups in the gut, faecal SCFA and faecal calprotectin did not differ
between Fe-deficient and Fe-sufficient children. Fe supplementation significantly improved Fe status in Fe-deficient children and did
not significantly increase faecal calprotectin concentration. Moreover, no significant effect of Fe treatment or time£ treatment interaction
on the concentrations of bacterial groups in the gut or faecal SCFA was observed compared with the placebo treatment. Also, there
were no significant differences observed in the concentrations of any of the bacterial target groups or faecal SCFA at 2, 12 or 38 weeks
between the three groups of children when correcting for baseline values. The present study suggests that in African children with a
low enteropathogen burden, Fe status and dietary Fe supplementation did not significantly affect the dominant bacterial groups in the
gut, faecal SCFA concentration or gut inflammation.
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Fe deficiency affects more than 2 billion people worldwide,
and children, because they require high amounts of Fe for
growth and development, are among the most vulnerable(1).
Fe deficiency can lead to Fe-deficiency anaemia and
impair school performance and cognitive development in
children(2,3). Thus, adequate dietary Fe availability for
school-aged children is critical. In the past, the WHO rec-
ommended that children living in the regions with a high
prevalence of Fe deficiency receive oral supplementation of
Fe as FeSO4
(1,4,5). This recommendation has been modified
in recent years because of concerns that Fe supplementation
may increase the risk for hospitalisations and mortality from
infections(6–9).
Supplemental Fe is poorly absorbed in the human gastroin-
testinal tract and most of the dose passes into the colon where
it becomes available for the gut microbiota. The symbiotic
bacteria in the gut provide the host with many beneficial
functions, such as colonisation resistance from pathogens,
immunomodulatory properties and degradation of indigestible
compounds, while producing bacterial metabolites, such as
SCFA, influencing host health and providing additional
energy to host cells(10,11). There are alterations in the com-
position of the gut microbiota in malnourished children in
developing countries, and it has been proposed that the
microbiota may contribute to the effects of nutritional
deficiencies in these settings(12–16). Several animal studies
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have suggested that host Fe status and dietary Fe availability
can influence the microbial ecosystem of the gut(17–22), and
that most bacteria in the gut have a requirement for Fe(23).
However, the impact of Fe status and dietary Fe availability
on the gut microbiota in humans is uncertain. A recent study
in India has reported decreased numbers of lactobacilli in
women with Fe-deficiency anaemia(24). Furthermore, two
studies in infants(25,26) and one randomised placebo-
controlled trial in Ivorian school children living in a rural
area with a high prevalence of environmental pathogens(9)
have reported changes in the composition of the gut micro-
biota after Fe fortification. It has also been shown that the
growth and infectivity of several enteropathogens can be pro-
moted by Fe supplementation in vitro (27) and also in hosts
with Fe overload(28). Both a dysbiosis of the gut microbiota,
and hence a reduced barrier effect and colonisation resistance
against pathogens(29), and enhanced pathogen growth due to
high-dose Fe supplementation could increase the risk for the
development of diarrhoea. Indeed, a systematic review and
a recent study in young children in Pakistan have found that
Fe supplementation may increase the incidence of diarrhoea
in children, especially in areas with a high prevalence of
enteric pathogens(6,30). Moreover, an increase in infection
with other pathogens due to Fe supplementation could have
an impact on the inflammatory preset of the host, which in
turn might alter the composition of the gut microbiota and
facilitate colonisation with enteropathogenic bacteria(8,29,31).
Based on these previous studies and observations, our
hypothesis was that high-dose Fe supplementation and also
host Fe status can affect the dominant commensal bacterial
groups in the gut, their main metabolites and gut inflam-
mation. This may lead to a potential dysbiosis of the gut
microbiota with less protection against the establishment
of environmental bacteria, such as enteropathogens, and
a change in the degradation of dietary compounds. To
test this hypothesis, we investigated the impact of oral
supplementation of Fe as FeSO4 over a time period of
38 weeks on the concentrations of dominant bacterial
groups in the gut, faecal SCFA and faecal calprotectin, a gut
inflammation marker, in Fe-deficient school children living
in rural South Africa compared with a placebo treatment
without FeSO4 over the same time period. We also included
non-treated Fe-sufficient children to investigate whether the
abundance of dominant bacterial groups, faecal SCFA concen-
tration and faecal calprotectin concentration differs between
Fe-sufficient and Fe-deficient children.
Subjects and methods
Study design
Participants included in the present study were 6- to 11-
year-old children (n 73) from two primary schools that serve
low-income rural villages in the Province of KwaZulu-Natal
in eastern South Africa (Fig. 1). A total of two groups of chil-
dren were randomly selected from two arms of a 2£2 study
design assessing the effects of Fe and n-3 fatty acid sup-
plementation, alone and in combination, on cognition in
school children, as reported previously(3). One group received
Fe supplements (Fe group, n 22) and another group received
placebo (placebo group, n 27). As described previously,
these children lived in a malaria-free region and fulfilled the
following inclusion criteria: (1) 6 to 11 years of age; (2) Hb
concentration .80 g/l; (3) Fe deficient (serum ferritin (SF)
concentration ,20mg/l or zinc protoporphyrin (ZnPP) con-
centration .70mmol/mol haem or serum transferrin receptor
(TfR) concentration .8·3 mg/l); (4) no chronic disease; (5) not
using Fe supplements(3).
Children in the Fe group were given orally one tablet con-
taining 50 mg Fe as FeSO4 (Lomapharm; Paul Lohmann
GmbH) together with a fruit-flavoured and vitamin C-enriched
(approximately 10 mg/serving) beverage (200 ml) for 4 d/week,
Fe-group
(n 22)
Placebo group
(n 27)
Fe-sufficient
 group (n 24)
Baseline
Analysis: Analysis: Analysis: Analysis:
Fe status
Weight/height-
for-age z score
Microbiota
composition
Microbiota
metabolites
Microbiota
composition
Microbiota
metabolites
Faecal
calprotectin
Microbiota
composition
Microbiota
metabolites
Faecal
calprotectin
2 weeks
Fe-supplements: 50 mg Fe tablets on 4 d/week
Placebo: tablets without Fe on 4 d/week
Midpoint
(12 weeks)
Endpoint
(38 weeks)
Fe status
Weight/height-
for-age z score
Microbiota
composition
Microbiota
metabolites
Faecal
calprotectin
Fig. 1. Summary of the study design with interventions in the placebo and iron groups as well as the different sampling time points and the corresponding
analysis.
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while those in the placebo group received an identical tablet
without Fe and the beverage(3). Trained fieldworkers (one
fieldworker per group and school) directly supervised the
tablet consumption and recorded compliance and self-
reported illness symptoms while absent and present. Children
in the placebo and Fe groups were dewormed with an oral
dose of 400 mg mebendazole (Be-Tabs Pharmaceuticals (Pyt)
Limited) 3 and 15 weeks after the start of the intervention trial.
A third group of children (Fe-sufficient group, n 24) with
highest SF concentrations (without inflammation, C-reactive
protein (CRP) concentration ,5 mg/l) and thereafter lowest
TfR and ZnPP concentrations was randomly selected out of
100 children from the same two schools; they participated in
the baseline screening, but were not included in the interven-
tion trial due to adequate Fe status. We enrolled this third
group as a reference group to compare the composition of
the gut microbiota between Fe-deficient and Fe-sufficient
children at baseline and to follow the changes in the gut
microbiota over time without the intervention.
In a previous study in Ivorian school children, a sample size
of thirty children per group was adequate to detect significant
differences in the major bacterial groups in the gut microbiota
after Fe fortification of 10 mg Fe/d(9). Since in the present
study, a much higher Fe dose (50 mg Fe, 4 d/week) was pro-
vided via oral supplementation, we estimated that a sample
size between twenty and thirty children per group would be
adequate to detect the differences between Fe supplemen-
tation and placebo treatment.
Trained local fieldworkers conducted two 24 h dietary
recalls 2 weeks apart on different days of the week. The
24 h dietary recalls were administered to the parents/carers
of sixty children per participating school in their local
language (Zulu). One recall per child was conducted for a
week day and one recall was conducted for a weekend day.
Dietary data were analysed with the Food Finder computer
program (Medical Research Council, 2003). Anthropometric
measurements were taken at baseline and endpoint, as
described previously(3). Age- and sex-specific height-for-age
z scores, weight-for-age z scores and BMI-for-age z scores
were calculated using the 2007 WHO growth standards for
children aged 5 to 19 years with the software WHO Anthro
Plus for personal computers (version 1.0.3, WHO, 2010).
Weight-for-age z scores were available only for children
,11 years of age. The present study was performed from Feb-
ruary to November 2010 and was interrupted by holidays for
2 weeks in March and April, for 5 weeks in June and July,
and for 1 week in September. Supplementation was further
interrupted for 4·5 weeks by a national strike of teachers in
August and September. To catch up on the unexpected loss
of intervention days, supplementation was increased from 4
to 5 d/week for 8 weeks, which compensated for 2 weeks of
supplementation. Thus, in total, supplements were provided
for 105 d over a period of 38 weeks. The present study was
conducted according to the guidelines laid down in the
Declaration of Helsinki, and all procedures including human
subjects were approved by the ethics committees of the
North-West University in South Africa and by the Swiss
Federal Institute of Technology Zu¨rich in Switzerland. Written
informed consent was obtained from parents, and verbal
consent of children was witnessed and formally recorded.
The present trial was registered at ClinicalTrials.gov as
NCT01092377.
Sample collection and blood sample analysis
Faecal samples were collected from 09.00 to 12.00 hours at four
time points throughout the study: at baseline just before the
start of the intervention, and at 2 weeks, 12 weeks (midpoint)
and 38 weeks (endpoint) of Fe supplementation (Fig. 1).
Faecal sample collection was specifically optimised to avoid
bacterial cell death by oxygen or bacterial growth due to
the lack of a constant low temperature before freezing.
The samples were collected immediately after defecation in
zip-lock bags containing an Anaerocult A mini bag (Merck
Millipore) to maintain anaerobiosis. Samples were kept at 48C
and within 6 h, aliquots were made in several 2 ml Eppendorf
tubes and frozen at 2808C until further analysis.
Blood samples were collected at baseline and endpoint,
as described previously(3). Briefly, venous blood samples
(10 ml) were drawn into EDTA-coated and trace-element free
tubes (Becton Dickinson) at baseline and endpoint. Hb con-
centrations were measured on site in the whole blood by the
direct cyanmethaemoglobin method (Ames Mini-Pak Hb test
pack and Ames Minilab; Bio-Rad Laboratories (PTY) Limited)
with Drabkin’s solution and a standard miniphotometer. The
remaining samples were centrifuged at 500g for 15 min at
room temperature, and plasma and serum aliquots were pre-
pared and stored at 2208C for the duration of the fieldwork
(4 d) and then at 2808C until analysis. Erythrocytes were
washed twice with 0·15 M-NaCl and centrifuged at 500 g for
10 min to remove the buffy coat. ZnPP was determined on
site on washed erythrocytes, as described previously(3). SF,
CRP and TfR concentrations were measured in serum, as
described previously(3). Fe deficiency during the intervention
was defined as a SF concentration ,15mg/l(32) or a ZnPP con-
centration .70mmol/mol haem(33) or a TfR concentration
.8·3 mg/l (test kit reference value), and anaemia was defined
as a Hb concentration ,115 g/l(4). For the reporting of pre-
valence and statistical analyses, a SF concentration ,15mg/l
was used to define Fe deficiency; for inclusion into the study,
an SF concentration,20mg/l was used. Systemic inflammation
was defined as a CRP concentration .5 mg/l.
Faecal sample DNA extraction and enumeration of
bacterial groups
Faecal samples were thawed on ice and total genomic
DNA was extracted using the FastDNA SPIN kit for soil (MP
Biomedicals), according to the manufacturer’s instructions.
Bacterial groups prevalent in the gut were enumerated using
specific primers for the 16S ribosomal RNA gene or a func-
tional gene (Table 1) by quantitative PCR (qPCR) analysis
performed with an ABI PRISM 7500-PCR sequence detection
system (Life Technologies), as described previously(34,35).
qPCR consisted of 2£ SYBR Green Mastermix (Life Tech-
nologies) or 2£ Kapa Sybr Fast qPCR Mastermix (Biolabo
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Scientifics Instruments), 0·2mM of each primer and 1ml of
template genomic DNA in a total volume of 25ml. Amplifica-
tion consisted of an initial denaturation step at 958C for
10 min (20 s for Kapa Sybr Fast qPCR Mastermix) followed
by forty cycles of 958C for 15 s (3 s) and 608C for 1 min
(30 s). A denaturation step was added to check for amplicon
specificity. The samples were analysed in duplicate and stan-
dard curves with the specific target 16S ribosomal RNA gene
or a functional gene were included in each run, as described
previously(34). Data were analysed with the 7500 Fast System
Sequence Detection Software (version 1.4; Life Technologies)
and expressed as the log number of 16S ribosomal RNA gene
copies or functional gene copies/g faeces.
Faecal SCFA concentration analysis
SCFA concentrations were analysed in the faecal samples
of a randomly selected subgroup of children (n 10 per
group) by HPLC. Briefly, 200–300 mg faeces were homogen-
ised with 1 ml of 0·15 mM-H2SO4 and subsequently centrifuged
at 48C and 9000 g for 20 min. The supernatants were diluted
1:1 with MilliQ water and filtered through a 0·45mm nylon
filter (Infochroma AG) before injection. HPLC (Hitachi
LaChrome; Merck) was performed using a Cation-H refill
cartridge (30£4·6 mm) connected to an Aminexw HPX-87H
(300£7·8 mm) column at a flow rate of 0·4 ml/min at 408C
and 10 mM-H2SO4 as the eluent solution. The samples were
analysed in duplicate and data expressed as mmol/g faeces.
Faecal calprotectin concentration analysis
Calprotectin concentration in the faecal samples of children
was measured by immunoassay (Calprest; Eurospital S.p.A),
according to the manufacturer’s instructions (placebo group,
n 12; Fe group, n 13; Fe-sufficient group, n 13), at baseline,
midpoint and endpoint. The samples were analysed in dupli-
cate and data expressed as mg/kg faeces.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics
(version 19; IBM Company). Data were checked for normal
distribution and transformed, if necessary. Outliers (^3 SD
from the mean) were removed from the analysis. At baseline,
all variables were compared between the groups using the
one-way ANOVA with post hoc Bonferroni correction for
multiple comparisons. At 2 weeks, midpoint and endpoint
of the study, variables were compared between the groups
(Fe group, placebo group and Fe-sufficient group) using
ANCOVA with corresponding baseline values as covariates.
Moreover, potential differences in qPCR data and HPLC data
by intervention group only (Fe and placebo groups) over
time were analysed using repeated-measures ANOVA, with
the sampling time point as the within-subject variable and
intervention group (Fe and placebo groups) as the between-
subject factor. When significant changes over time were
detected, repeated-measures ANOVA was performed for
each variable between baseline and the subsequent time
points within each group separately to detect deviations
from baseline levels. qPCR data, TfR, ZnPP, SF, CRP and cal-
protectin data were log transformed for statistical analyses.
P,0·05 was considered as significant.
Results
Iron status, inflammation and anthropometric
measurements of the study subjects
Anthropometric measurements, Hb concentration, Fe status
indices and markers of systemic (CRP) and gut (calprotectin)
inflammation are shown in Table 2. At baseline, both
Table 1. Primers used to enumerate selected bacterial target groups by quantitative PCR
Primers Sequence 50 –30 Target group Reference
Eub338F 50-ACTCCTACGGGAGGCAGCAG-30 Total bacteria Guo et al.(48)
Eub518R 50-ATTACCGCGGCTGCTGG-30
Bac303F 50-GAAGGTCCCCCACATTG-30 Bacteroides spp. Ramirez-Farias et al.(49)
Bfr-Femrev 50-CGCKACTTGGCTGGTTCAG-30
Firm934F 50-GGAGYATGTGGTTTAATTCGAAGCA-30 Firmicutes Guo et al.(48)
Firm1060R 50-AGCTGACGACAACCATGCAC-30
Clep866mF 50-TTAACACAATAAGTWATCCACCTGG-30 Clostridium Cluster IV Ramirez-Farias et al.(49)
Clep1240mR 50-ACCTTCCTCCGTTTTGTCAAC-30
RrecF 50-GCGGTRCGGCAAGTCTGA-30 Roseburia spp./E. rectale Furet et al.(50)
Rrec630mR 50-CCTCCGACACTCTAGTMCGAC-30
Fprau223F 50-GATGGCCTCGCGTCCGATTAG-30 Faecalibacterium prausnitzii Bartosch et al.(51)
Fprau420R 50-CCGAAGACCTTCTTCCTCC-30
EhalF 50-GCGTAGGTGGCAGTGCAA-30 Eubacterium hallii Ramirez-Farias et al.(49)
EhalR 50-GCACCGRAGCCTATACGG-30
dsrA_F336 50-CTGCGAATATGCCTGCTACA-30 SRB, dsrA gene Pereyra et al.(52)
dsrA_R533 50-TGGTCGARCTTGATGTCGTC-30
F_Lacto 05 50-AGCAGTAGGGAATCTTCCA-30 Lactobacillus/Pediococcus/Leuconostoc spp. Furet et al.(50)
R_Lacto 04 50-CGCCACTGGTGTTCYTCCATATA-30
xfp-fw 50-ATCTTCGGACCBGAYGAGAC-30 Bifidobacteria phosphoketolase Cleusix et al.(53)
xfp-rv 50-CGATVACGTGVACGAAGGAC-30
Eco1457F 50-CATTGACGTTACCCGCAGAAGAAGC-30 Enterobacteriaceae Bartosch et al.(51)
Eco1652R 50-CTCTACGAGACTCAAGCTTGC-30
SRB, sulphate-reducing bacteria; dsrA, dissimilatory sulphite-reductase subunit A.
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Table 2. Baseline and endpoint parameters of iron status, inflammation as well as anthropometric measurements
of children included in the study*
(Mean values with their standard errors; medians and maximum and minimum values)
Placebo group
(n 27)
Fe group
(n 22)
Fe-sufficient
group (n 24)
Mean SEM Mean SEM Mean SEM P†
Age (years) 9·1 0·2 9·1 0·3 8·3 0·3
Sex
Female
n 17 11 12
% 61 50 50
Hb (g/l)
Baseline 119·1b 1·7 120·6b 1·6 129·6a 1·1
Endpoint 125·8 1·9 129·1 1·7 0·266
Serum transferrin receptor (mg/l)‡
Baseline
Median 5·9a 6·0a 4·5b
Minimum–maximum 2·8–11·7 3·3–10·2 3·2–6·7
Endpoint
Median 8·4 6·9 ,0·001
Minimum–maximum 6·2–14·4 4·6–8·4
Zinc protoporphyrin (mmol/mol haem)‡
Baseline
Median 76·5a 74·5a 46·0b
Minimum–maximum 40·0–171·0 43·0–127·0 31·0–73·0
Endpoint
Median 77·8 68·5 0·131
Minimum–maximum 35·5–202·5 40·5–126·0
Serum ferritin§ (mg/l)‡
Baseline
Median 18·9b 20·7b 56·9a
Minimum–maximum 3·8–58·1 11·5–54·7 35·0–105
Endpoint
Median 25·4 56·7 ,0·001
Minimum–maximum 4·4–100·0 23·6–178·0
CRP (mg/l)‡
Baseline
Median 0·0 0·4 0·6
Minimum–maximum 0–4·9 0–12·7 0–19·6
Endpoint
Median 0·3 0·3 0·304
Minimum–maximum 0–7·3 0–2·2
Weight-for-age z score
Baseline 0·33 0·23 20·02 0·35
Endpoint 0·32 0·27 0·44 0·32 0·710
Height-for-age z score
Baseline 20·67 0·17 20·66 0·24
Endpoint 20·55 0·19 20·70 0·25 0·111
BMI-for-age z score
Baseline 0·61 0·19 0·35 0·24
Endpoint 0·46 0·18 0·36 0·24 0·293
Faecal calprotectin (mg/kg faeces)‡k
Baseline
Median 60·3 139·0 78·1
Minimum–maximum 24·6–501·4 17·3–449·1 16·8–463·8
Midpoint
Median 31·2 59·7 115·0 0·501
Minimum–maximum 18·4–306·0 17·8–361·3 16·4–565·6
Endpoint
Median 69·8 59·7 60·5 0·865
Minimum–maximum 15·6–490·5 17·1–476·3 19·8–536·7
CRP, C-reactive protein.
a,b Mean values with unlike superscript letters were significantly different (P,0·05; one-way ANOVA with post hoc Bonferroni
correction).
* No Fe status indices and anthropometric measurements were available for children in the Fe-sufficient group at the endpoint.
† Midpoint (only for faecal calprotectin) and endpoint variables were compared between the groups using ANCOVA with respective
baseline values as covariates.
‡ Data were log transformed for statistical analyses.
§ Only those children were considered whose CRP concentrations were ,5 mg/l.
kPlacebo group, n 12; Fe group, n 13; Fe-sufficient group, n 13.
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Fe-deficient groups (placebo and Fe groups) had significantly
lower Hb and lower Fe status than the Fe-sufficient group. The
prevalence of Fe deficiency based on the concentrations of
TfR and SF in the Fe group was 18·2 and 9·1 %, respectively,
and in the placebo group 18·5 and 29·6 %, respectively. More-
over, 25·9 % of the children in the placebo group and 13·6 % of
the children in the Fe group were anaemic, while none of the
children in the Fe-sufficient group were anaemic. There was a
significant intervention effect (ANCOVA with baseline values
as covariates) of Fe supplementation for lower TfR concen-
trations (P,0·001) and higher SF concentrations (P,0·001)
at the endpoint in the Fe group compared with the placebo
group. Fe supplementation did not affect the concentration
of CRP. Faecal calprotectin concentrations did not differ
between the groups at baseline, midpoint and endpoint, and
were not affected by Fe supplementation.
Dietary assessment done in the study population found a
mean background dietary Fe intake of 9·8 (SEM 0·3) mg/d.
The incidence of illness was recorded during the entire trial
period, and the mean days absent from school due to illness
was 1·3 (SEM 0·3) d and due to gastrointestinal illness (diar-
rhoea, stomach pain and/or vomiting) was 0·3 (SEM 0·1) d in
children included in the present study. Moreover, the mean
days absent due to all illness and gastrointestinal illness did
not differ between the Fe (all illness: 1·2 (SEM 0·4) d; gastro-
intestinal illness: 0·2 (SEM 0·1) d) and placebo (all illness: 1·3
(SEM 0·4) d; gastrointestinal illness: 0·3 (SEM 0·2) d) groups.
Concentrations of dominant bacterial groups
Total 16S ribosomal RNA gene copies were stable over the
entire trial period, and no differences were observed between
the treatment groups across the different time points (Fig. 2).
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Fig. 2. Log number of 16S ribosomal RNA gene copies or functional gene copies/g faeces of selected bacterial target groups in the gut microbiota of children in
the placebo group ( ), iron group ( ) and iron-sufficient group ( ) at (a) baseline, (b) 2 weeks, (c) midpoint and (d) endpoint. No significant treatment£ time
interaction was detected using repeated-measures ANOVA, with the sampling time point as the within-subject variable and intervention group (iron and
placebo groups) as the between-subject factor. Values are means, with their standard errors represented by vertical bars. * Mean value was significantly
different from that of baseline concentrations of the same bacterial target group within a treatment group (P,0·05; repeated-measures ANOVA). SRB,
sulphate-reducing bacteria.
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At baseline, measured gut bacterial populations did not
differ between the children who were Fe deficient (placebo
and Fe groups) and those with an adequate Fe status
(Fe-sufficient group). There was a trend observed towards
lower concentrations of Enterobacteriaceae in the faeces of
children in the Fe group compared with the Fe-sufficient
group (P¼0·064).
With baseline concentrations as covariates, there were no
significant differences observed between the groups in terms
of concentrations of any of the measured bacterial target
groups at 2 weeks, midpoint or endpoint of the study.
Moreover, no significant effects of Fe treatment or time£
treatment interaction were observed when analysing each
bacterial target group over time and including only the
placebo and Fe groups in the analysis. However, there were
significant effects for time within the groups, when comparing
bacterial concentrations at 2 weeks, midpoint and endpoint
with baseline. As shown in Fig. 2, Bacteroides spp. signifi-
cantly increased in the placebo (P¼0·004) and Fe (P¼0·004)
groups from baseline to the endpoint, while Eubacterium
hallii concentrations significantly decreased in the placebo
(P,0·001), Fe (P¼0·024) and Fe-sufficient (P,0·001)
groups, and sulphate-reducing bacteria concentrations signifi-
cantly decreased only in the Fe-sufficient (P¼0·03) and Fe
(P¼0·008) groups from baseline to the endpoint. Concen-
trations of Lactobacillus/Leuconostoc/Pediococcus spp. signifi-
cantly decreased from baseline to the endpoint (P¼0·027) in
the placebo group, and Faecalibacterium prausnitzii concen-
trations decreased from baseline to the endpoint (P¼0·004)
in the Fe-sufficient group. Furthermore, concentrations of
F. prausnitzii increased from baseline to the midpoint
(P¼0·045) in the Fe group, which was not observed in the
placebo group or the Fe-sufficient group (Fig. 3).
Faecal SCFA concentrations
Baseline faecal acetate, propionate and butyrate con-
centrations did not differ between the placebo, Fe and
the Fe-sufficient groups (Fig. 4(a)–(c), respectively). Also,
the baseline ratios of acetate:propionate:butyrate did not
differ between the placebo (59:28:13), Fe (58:27:15) and
Fe-sufficient (56:30:14) groups.
With baseline values as covariates, there were no signi-
ficant differences observed in faecal acetate, propionate and
butyrate concentrations between the three groups at 2 weeks,
midpoint or endpoint of the study. Furthermore, no significant
effects for Fe treatment and time£ treatment interaction were
found for SCFA production by the gut microbiota when
including only the Fe and placebo groups in the analysis.
However, there were significant effects for time within the
Fe and placebo groups (but not within the Fe-sufficient
group) when comparing the concentrations of metabolites
during the intervention with those at baseline. Acetate concen-
trations significantly increased from baseline to 2 weeks
(P¼0·026) in the Fe group (Fig. 4(a)). In the placebo group,
acetate concentrations significantly increased from baseline
to the endpoint (P¼0·009). In the Fe and placebo groups,
butyrate concentrations significantly increased from baseline
to 2 weeks (P¼0·001 and P¼0·002, respectively) and to the
endpoint (P¼0·034 and P¼0·040, respectively; Fig. 4(c)). At
midpoint, butyrate concentrations remained significantly
higher than those at baseline in the Fe group (P¼0·040).
There were no significant effects of time on propionate
concentrations within the groups (Fig. 4(b)).
Discussion
The present study was the first randomised, placebo-
controlled Fe intervention trial to investigate the impact of
oral Fe supplementation on gut microbiota and gut inflam-
mation in African children. The major finding of the present
study is that high-dose Fe supplementation (50 mg Fe,
4 d/week) over a period of 38 weeks did not significantly
modify the concentrations of dominant bacterial groups in
the gut or faecal SCFA, and did not increase gut inflammation.
A second important finding is that the dominant bacterial
groups prevalent in the gut and faecal SCFA concentrations
of Fe-sufficient children were not different from those of
Fe-deficient children.
We found no effect of Fe supplementation on the abun-
dance of dominant bacterial groups in the gut compared
with the placebo treatment. These findings are in sharp con-
trast to the previous study in similarly aged children living
in rural Coˆte d’Ivoire, where daily provision of Fe-fortified
biscuits (10 mg Fe as electrolytic Fe) to school children
for 6 months significantly increased Enterobacteriaceae and
decreased lactobacilli concentrations(9). This difference may
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Fig. 3. Log number of 16S ribosomal RNA (rRNA) gene copies/g faeces of
Faecalibacterium prausnitzii in the faecal samples of children in the placebo
group (n 27, ), iron group (n 22, ) and iron-sufficient group (n 24, )
measured over time by quantitative PCR. No significant treatment£ time
interaction was detected using repeated-measures ANOVA, with the
sampling time point as the within-subject variable and intervention group
(iron and placebo groups) as the between-subject factor. Values are means,
with their standard errors represented by vertical bars. * Mean value was sig-
nificantly different from that of baseline concentrations within a treatment
group (P,0·05; repeated-measures ANOVA).
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be at least partially explained by the fact that Ivorian children
lived in a remote rural area with poorer-quality water and
food sanitation, a more monotonous low-quality diet and a
higher infectious disease burden (including enteropathogens
and malaria). Colonic Fe can promote the growth and viru-
lence of certain pathogens(36–38). During enteropathogen
infection and the resulting inflammation, the composition of
the gut microbiota is shifted towards facultative anaerobes
such as enterobacteria(29,39–42), and high colonic Fe
concentrations may contribute to these effects by aggravating
inflammation(18,43). The children in the present study were
mainly from households with access to relatively clean tap
water and lived in a malaria-free environment. In addition,
the schools in this area of South Africa participated in the
National School Nutrition Program, where children were
offered a daily school meal that contributes to nutritional
diversity. Nevertheless, studies in infants have shown an
impact of additional dietary Fe supplementation on the gut
microbiota even in industrialised countries with a low entero-
pathogen burden(26,44). However, the gut microbiota in infants
is in the process of developing into a fully diversified bacterial
ecosystem. This still fragile bacterial consortium may be
more vulnerable to alterations in luminal Fe status than a
fully diversified and stable gut microbiota such as that found
in the 6- to 11-year-old children of the present study.
We also found that the abundance of dominant bacterial
groups and faecal SCFA concentrations did not differ between
Fe-deficient (Fe and placebo groups) and Fe-sufficient
children. This is in contrast with several animal studies that
associated Fe deficiency with changes in the composition of
the gut microbiota(17,18,24). Animal and in vitro studies have
further shown that Fe deficiency modifies the metabolic
activity of the gut microbiota, resulting in a decrease in buty-
rate production(21,34). These differences from our findings may
be due to the differences in the severity of Fe deficiency
among the studies. Most of the children included in the pre-
sent study were only mildly Fe deficient. South Africa fortifies
wheat flour and maize meal with Fe, and the mean daily Fe
intake in the present study population was found to be 9·8
(SEM 0·3) mg(3,45). Thus, colonic luminal Fe concentrations in
children of the present study were unlikely to have been
very low. In previous in vitro studies, we have shown that a
dietary Fe concentration in this range is sufficient to maintain
a stable gut microbiota(34).
During the study, there was an overall decrease observed in
the concentrations of faecal lactobacilli, E. hallii, F. prausnitzii
and sulphate-reducing bacteria, while concentrations of
Bacteroides spp. slightly increased from baseline to the end-
point in all the treatment groups. Since these changes were
independent of Fe supplementation and also observed in
the Fe-sufficient group, we assume that either seasonal
changes or other alterations in dietary habits during the
intervention (including a long school vacation between the
midpoint and the endpoint, with no school lunch provided)
may be responsible for these time effects.
SCFA acetate, propionate and butyrate are the major meta-
bolites of the gut microbiota. In the present study, no
differences in SCFA were observed between Fe-sufficient
and Fe-deficient children at baseline, and Fe supplementation
did not affect faecal SCFA concentrations. This is in contrast to
previous studies in rats, where Fe supplementation increased
the metabolic activity of the microbiota, particularly
butyrate(21,22). However, generally, only about 5 % of the
SCFA produced by the gut microbiota are excreted in the
faeces; the remainder are readily absorbed by the host, which
can lead to large variations in faecal SCFA concentrations(46).
Nevertheless, faecal acetate or butyrate concentrations were
modified in the Fe and placebo groups over time, which may
be explained by seasonal alterations in diet or other factors, as
discussed above, for the composition of the gut microbiota.
Because high luminal Fe concentrations can promote
inflammation(18,43), in the present study, we assessed systemic
inflammation by serum CRP and local colonic inflammation
by faecal calprotectin, a peptide secreted by neutrophils infil-
trating the gut mucosa. Serum CRP and faecal calprotectin
concentrations did not differ between Fe-sufficient and Fe-
deficient children at baseline. Furthermore, in this setting,
high-dose Fe supplementation in Fe-deficient children did
not measurably increase systemic or gut inflammation. Thus,
our findings differ from the study conducted in rural Coˆte
d’Ivoire, where provision of Fe-fortified biscuits increased
faecal calprotectin concentrations compared with a control
group(9). However, in that study, Fe fortification increased
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Fig. 4. (a) Acetate, (b) propionate and (c) butyrate concentrations in the
faecal samples of children in the placebo group ( ), iron group ( ) and
iron-sufficient group ( ) at baseline, 2 weeks, midpoint and endpoint of the
study. No significant treatment£ time interaction was detected using
repeated-measures ANOVA, with the sampling time point as the within-sub-
ject variable and intervention group (iron and placebo groups) as the
between-subject factor. Values are means (n 9–10 children per group and
time point), with their standard errors represented by vertical bars. * Mean
value was significantly different from that of baseline concentrations of the
same metabolite within a treatment group (P,0·05; repeated-measures
ANOVA).
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enterobacteria numbers (including many potential entero-
pathogens causing gut inflammation), which correlated with
faecal calprotectin. In the present study, the overall incidence
of diarrhoea during the intervention was very low with an
average of only 0·1 (SEM 0·1) d absent due to gastrointestinal
illness, and no differences between Fe- and placebo-
supplemented children were observed. However, clinical
data should be interpreted with caution, as they were based
on self-reporting and the sample size of the present study
was small. Calprotectin concentrations in our children were
generally higher than those previously reported in African
children at this age(9,47).
In summary, in South African school-aged children from a
malaria-free rural area with a low gastrointestinal disease
burden, we found no significant differences in the abundance
of dominant bacterial groups or faecal SCFA concentrations
in mildly Fe-deficient and non-Fe-deficient children. This
suggests that dietary and luminal Fe levels in both groups
were sufficient to maintain the gut microbiota. Furthermore,
high-dose Fe supplementation had no measurable impact on
the abundance of dominant bacterial groups in the gut,
faecal SCFA concentration or gut inflammation. Therefore, it
appears that Fe supplementation poses a low risk for negative
modulation of the tested bacterial groups and/or adverse
intestinal effects at this age and in this setting. Hence, our
initial hypothesis that high-dose Fe supplementation would
modify the tested bacterial groups and metabolites under all
conditions could not be confirmed. The effects of Fe
supplementation on the gut microbiota most probably also
depend on environmental factors (e.g. presence of entero-
pathogens) and gut inflammatory preset of the host. Future
research should therefore investigate the potential effects
of Fe supplementation on the gut microbiota in other age
groups, in populations where Fe deficiency is more severe,
and in settings where poor-quality water and food supplies
increase exposure to potential enteropathogens.
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